Article
Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer.
Clinical drug investigation - 1 Nov 2018
Hoste Griet, Slembrouck Laurence, Jongen Lynn, Punie Kevin, Matton Tom, Vander Borght Sara, Vanden Bempt Isabelle, Menten Johan, Wildiers Hans, Floris Giuseppe, Arteaga Carlos, Neven Patrick
Abstract excerpt
We present the case of a postmenopausal patient with a secondary metastatic ER-positive, HER2-negative breast cancer who was successfully treated with fulvestrant and alpelisib following six lines of therapy. The tumour showed two uncommon PIK3CA mutations, and with the combination of alpelisib and fulvestrant the patient went from ECOG grade 3, before the start of this therapy, to ECOG grade 1 during treatment...
Topics
Join the communities discussing this publication.